ORAL-CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN

被引:21
|
作者
BERKOWITZ, GS
KELSEY, JL
LIVOLSI, VA
HOLFORD, TR
MERINO, MJ
ORT, S
OCONNOR, TZ
GOLDENBERG, IS
WHITE, C
机构
[1] MT SINAI MED CTR, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA
[2] YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA
[3] YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA
[4] YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06510 USA
[5] MT SINAI MED CTR, DEPT COMMUNITY MED, NEW YORK, NY 10029 USA
[6] COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10027 USA
[7] UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA
[8] YALE UNIV, SCH MED, CTR CHILD STUDY, NEW HAVEN, CT 06510 USA
关键词
D O I
10.1093/oxfordjournals.aje.a113878
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The association between use of oral contraceptives and fibrocystic breast disease was assessed among women aged 20-74 yr in a hospital-based case-control study conducted between Nov. 1979 and Nov. 1981 in Connecticut USA. The study groups comprised 633 women with biopsy-proven fibrocystic breast disease and 1062 controls who had been admitted, as inpatients or outpatients, to general surgical services. For the premenopausal women, there was no evidence that long-term use of oral contraceptives was associated with a decreased frequency of fibrocystic breast disease among either current or past users. For the postmenopausal women, previous oral contraceptive exposure was associated with an increased occurrence of cystic disease. These findings contradict previous investigations reporting a negative association between oral contraceptive use and the development of fibrocystic breast disease.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 50 条
  • [21] EFFECTS OF AN ORAL-CONTRACEPTIVE ON HEPATIC SIZE AND ANTIPYRINE METABOLISM IN PREMENOPAUSAL WOMEN
    HOMEIDA, M
    HALLIWELL, M
    BRANCH, RA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1978, 24 (02) : 228 - 232
  • [22] ORAL-CONTRACEPTIVE USE AND BREAST-CANCER
    BAULIEU, EE
    BENAGIANO, G
    BROSENS, I
    COOKE, ID
    GOLDZIEHER, JW
    HAMMERSTEIN, JW
    HASPELS, A
    JOHANNISSON, E
    LUNENFELD, B
    POTTS, M
    BRITISH JOURNAL OF CANCER, 1987, 56 (05) : 706 - 706
  • [23] BREAST-CANCER AMONG YOUNG UNITED-STATES WOMEN IN RELATION TO ORAL-CONTRACEPTIVE USE
    WHITE, E
    MALONE, KE
    WEISS, NS
    DALING, JR
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07): : 505 - 514
  • [24] ORAL-CONTRACEPTIVE USE IN RELATION TO BREAST-CANCER RISK AMONG US BLACK-WOMEN
    PALMER, J
    ROSENBERG, L
    RAO, RS
    SHAPIRO, S
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 139 (11) : S68 - S68
  • [25] ORAL-CONTRACEPTIVE USE AND PREMENOPAUSAL BREAST-CANCER IN SWEDEN AND NORWAY - POSSIBLE EFFECTS OF DIFFERENT PATTERN OF USE
    LUND, E
    MEIRIK, O
    ADAMI, HO
    BERGSTROM, R
    CHRISTOFFERSEN, T
    BERGSJO, P
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1989, 18 (03) : 527 - 532
  • [27] ORAL-CONTRACEPTIVE USE AND BREAST-CANCER RISK IN YOUNG-WOMEN
    CHILVERS, C
    LANCET, 1989, 1 (8645): : 973 - 982
  • [28] ORAL-CONTRACEPTIVE USE AND BREAST-CANCER IN YOUNG-WOMEN IN SWEDEN
    OLSSON, H
    OLSSON, ML
    MOLLER, TR
    RANSTAM, J
    HOLM, P
    LANCET, 1985, 1 (8431): : 748 - 749
  • [29] ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER IN YOUNG-WOMEN
    RUBIN, GL
    WEBSTER, LA
    STADEL, B
    WINGO, PA
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1985, 8 (03): : A88 - A88
  • [30] ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER IN YOUNG-WOMEN
    RUBIN, G
    WEBSTER, L
    STADEL, B
    WINGO, P
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 122 (03) : 516 - 516